PTC Therapeutics, Inc. (PTCT) Stock

PTC Therapeutics, Inc. (PTCT) is a Healthcare stock trading at $78.92 (as of 2026-06-18), with a market capitalization of $612.58M and a trailing P/E of -34.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for patients with rare disorders. It markets products such as Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi across multiple regions, and it has product candidates in clinical, pre-clinical, and research stages, including PTC518.

Valuation — source: SEC EDGAR (first-party)
Price$78.92
Market Cap$612.58M
P/E Ratio-34.3
EV / EBITDA-33.0
Price / Book-3.61
Price / Sales0.79
DCF Value (model)$153.05
DCF Upside vs Price93.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.73B
Net Margin39.4%
Return on Equity103.5%
Debt / Equity-3.17
Current Ratio2.44
Revenue Growth (YoY)-76.8%
EPS Growth (YoY)-100.3%
FCF Growth (YoY)-106.9%
Financial Health — source: SEC EDGAR
Altman Z-Score1.96 (grey)
Valuation vs Sector & Industry
Stock P/E-34.3
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-263.6%
vs Industry-298.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($882.20M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMatthew Klein
Employees939
CountryUS
IPO Date2013-06-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Nuvalent, Inc. (NUVL)
  • Krystal Biotech, Inc. (KRYS)
  • Rhythm Pharmaceuticals, Inc. (RYTM)
  • Kymera Therapeutics, Inc. (KYMR)
  • Vaxcyte, Inc. (PCVX)
  • Silexion Therapeutics Ltd. (SLXN)
  • Cogent Biosciences, Inc. (COGT)
  • Protagonist Therapeutics, Inc. (PTGX)
PTCT earnings history · PTCT institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.